title: Female sexual dysfunction in patients treated with antidepressant-comparison between escitalopram and fluoxetine.
abstract: BACKGROUND
  Selective serotonin reuptake inhibitor is one of the most widely used antidepressant and commonly associated with female sexual dysfunction (FSD).
  
  
  OBJECTIVE
  This study compares the prevalence of FSD between patients on escitalopram and fluoxetine. The risk factors for FSD were also examined.
  
  
  METHODS
  A cross-sectional study involved 112 female depressed patients (56 each group) who were in remission (as defined in the fourth edition of Diagnostic and Statistical Manual of Mental Disorders [DSM-IV] during the past 2 months with no significant signs or symptoms of the disturbance and Montgomery-Asberg Depression Rating Scale score of ≤10) from the psychiatric clinic in a university hospital. The rates of sexual dysfunction between the two groups were compared.
  
  
  METHODS
  The subjects were interviewed by using Structured Clinical Interview for DSM-IV. Sexual dysfunction was assessed with the Malay Version of the Female Sexual Function Index.
  
  
  RESULTS
  The prevalence of FSD was 44.6% for all patients, 55.4% for the fluoxetine group, and 33.9% for the escitalopram group. Multivariate logistic regression analysis showed no significant difference in the risk of FSD between the two groups. Moderate to high dosing was the only significant associated factor for FSD (odds ratio = 4.89, 95% confidence interval = 1.94-12.33).
  
  
  CONCLUSIONS
  There was no significant difference in the risk of having FSD between patients treated with fluoxetine or escitalopram. Patients on higher dosage of antidepressant have higher risk of having FSD.
authors.affiliation: Department of Psychiatry, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia.
authors.forename: Hatta
authors.initials: H
authors.lastname: Sidi
authors.forename: Duni
authors.initials: D
authors.lastname: Asmidar
authors.forename: Rozita
authors.initials: R
authors.lastname: Hod
authors.forename: Ng Chong
authors.initials: NC
authors.lastname: Guan
mesh_terms: D000328:Adult; D015283:Citalopram / Q000009:adverse effects* / Q000627:therapeutic use; D003430:Cross-Sectional Studies; D003865:Major Depressive Disorder / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D005260:Female; D005473:Fluoxetine / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007406:Interview, Psychological; D015995:Prevalence; D011569:Psychiatric Status Rating Scales; D011581:Psychological Tests; D012307:Risk Factors; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D012735:Sexual Dysfunction, Physiological / Q000139:chemically induced* / Q000453:epidemiology
chemical_list: D015283:Citalopram; D005473:Fluoxetine; D017367:Selective Serotonin Reuptake Inhibitors